BR112012015170A8 - Derivado de amino-heteroarila, composição farmacêutica, uso de um derivado de amino-heteroarila, e, método para tratamento de dor - Google Patents
Derivado de amino-heteroarila, composição farmacêutica, uso de um derivado de amino-heteroarila, e, método para tratamento de dorInfo
- Publication number
- BR112012015170A8 BR112012015170A8 BR112012015170A BR112012015170A BR112012015170A8 BR 112012015170 A8 BR112012015170 A8 BR 112012015170A8 BR 112012015170 A BR112012015170 A BR 112012015170A BR 112012015170 A BR112012015170 A BR 112012015170A BR 112012015170 A8 BR112012015170 A8 BR 112012015170A8
- Authority
- BR
- Brazil
- Prior art keywords
- pain
- treatment
- aminoheteroaryl
- derivative
- pharmaceutical composition
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 125000005214 aminoheteroaryl group Chemical group 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28918209P | 2009-12-22 | 2009-12-22 | |
| EP09180321 | 2009-12-22 | ||
| PCT/EP2010/070213 WO2011076723A1 (en) | 2009-12-22 | 2010-12-20 | Amino-heteroaryl derivatives as hcn blockers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112012015170A2 BR112012015170A2 (pt) | 2016-03-29 |
| BR112012015170A8 true BR112012015170A8 (pt) | 2017-12-26 |
Family
ID=42045216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012015170A BR112012015170A8 (pt) | 2009-12-22 | 2010-12-20 | Derivado de amino-heteroarila, composição farmacêutica, uso de um derivado de amino-heteroarila, e, método para tratamento de dor |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8952001B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2516397B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5728024B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20120095481A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102884048B (cg-RX-API-DMAC7.html) |
| AR (1) | AR079543A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010335231C1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012015170A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2783209C (cg-RX-API-DMAC7.html) |
| MX (1) | MX2012007426A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2549546C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011076723A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5917503B2 (ja) * | 2011-05-19 | 2016-05-18 | 株式会社東芝 | モリブデン造粒粉の製造方法 |
| US9163008B2 (en) | 2011-09-02 | 2015-10-20 | Purdue Pharma, L.P. | Pyrimidines as sodium channel blockers |
| WO2013072758A1 (en) | 2011-11-15 | 2013-05-23 | Purdue Pharma L.P. | Pyrimidine diol amides as sodium channel blockers |
| CN104363908B (zh) * | 2012-05-30 | 2017-12-22 | 霍夫曼-拉罗奇有限公司 | 吡咯烷基杂环类 |
| CN106588803A (zh) * | 2016-11-16 | 2017-04-26 | 西南科技大学 | 一种制备5‑乙酰基异噁唑的新方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4606757A (en) * | 1982-12-23 | 1986-08-19 | The Dow Chemical Company | Diphenoxymethylpyridines having herbicidal properties |
| KR100197583B1 (ko) | 1997-02-04 | 1999-06-15 | 이민화 | 환자용모니터를 구비한 초음파진단장치 |
| US7329510B2 (en) | 2000-05-24 | 2008-02-12 | N.V. Organon | Full length human HCN1Ih channel subunit and variants |
| US6967211B2 (en) * | 2001-04-10 | 2005-11-22 | Nippon Shinyaku Co. Ltd. | Remedial agent for chronic articular rheumatism |
| US6980419B2 (en) | 2003-03-12 | 2005-12-27 | Zonare Medical Systems, Inc. | Portable ultrasound unit and docking station |
| JP2008513084A (ja) | 2004-09-17 | 2008-05-01 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | ワイヤレス超音波システムディスプレイ |
| US20070135437A1 (en) * | 2005-03-04 | 2007-06-14 | Alsgen, Inc. | Modulation of neurodegenerative diseases |
| PL2848610T3 (pl) * | 2006-11-15 | 2018-01-31 | Ym Biosciences Australia Pty | Inhibitory aktywności kinazy |
| PE20091524A1 (es) * | 2007-12-19 | 2009-09-25 | Palau Pharma Sa | Derivados de 2-aminopirimidina |
| CA2716109C (en) * | 2008-02-28 | 2016-07-19 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
| TW201022233A (en) | 2008-11-04 | 2010-06-16 | Organon Nv | (Pyrrolidin-2-yl)phenyl derivatives |
-
2010
- 2010-12-20 AR ARP100104763A patent/AR079543A1/es unknown
- 2010-12-20 MX MX2012007426A patent/MX2012007426A/es active IP Right Grant
- 2010-12-20 CN CN201080064520.9A patent/CN102884048B/zh not_active Expired - Fee Related
- 2010-12-20 WO PCT/EP2010/070213 patent/WO2011076723A1/en not_active Ceased
- 2010-12-20 AU AU2010335231A patent/AU2010335231C1/en not_active Ceased
- 2010-12-20 JP JP2012545268A patent/JP5728024B2/ja not_active Expired - Fee Related
- 2010-12-20 KR KR1020127019218A patent/KR20120095481A/ko not_active Withdrawn
- 2010-12-20 CA CA2783209A patent/CA2783209C/en not_active Expired - Fee Related
- 2010-12-20 RU RU2012131279/04A patent/RU2549546C2/ru not_active IP Right Cessation
- 2010-12-20 EP EP10795690.6A patent/EP2516397B1/en not_active Not-in-force
- 2010-12-20 BR BR112012015170A patent/BR112012015170A8/pt not_active Application Discontinuation
- 2010-12-20 US US13/518,427 patent/US8952001B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP5728024B2 (ja) | 2015-06-03 |
| CN102884048B (zh) | 2014-07-23 |
| CA2783209C (en) | 2017-03-14 |
| RU2012131279A (ru) | 2014-01-27 |
| WO2011076723A1 (en) | 2011-06-30 |
| AU2010335231B2 (en) | 2014-09-11 |
| RU2549546C2 (ru) | 2015-04-27 |
| US20120264728A1 (en) | 2012-10-18 |
| AR079543A1 (es) | 2012-02-01 |
| US8952001B2 (en) | 2015-02-10 |
| CN102884048A (zh) | 2013-01-16 |
| AU2010335231A1 (en) | 2012-06-21 |
| AU2010335231C1 (en) | 2015-04-16 |
| KR20120095481A (ko) | 2012-08-28 |
| BR112012015170A2 (pt) | 2016-03-29 |
| EP2516397B1 (en) | 2016-07-13 |
| MX2012007426A (es) | 2012-07-23 |
| EP2516397A1 (en) | 2012-10-31 |
| CA2783209A1 (en) | 2011-06-30 |
| JP2013515031A (ja) | 2013-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015032623A2 (pt) | composto, composição farmacêutica, métodos para tratar doenças e condições, e para degradar o receptor de estrogênio, usos de um composto e de uma combinação, e, combinação | |
| BRPI0507198A (pt) | derivados de bisariluréia | |
| BR112012022211A2 (pt) | composto. composição farmacêutica, método de tratamento de uma doença meidada por h4r, método de inibição de h4h, método de tratamento da dor ou inflamação resultante de cirurgia de catarata, método para atingir um efeito em um paciente e uso de uma composto | |
| CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
| UA95644C2 (ru) | Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний | |
| CL2012002423A1 (es) | Método para tratar lupus nefritis activo que comprende administrar al paciente laquinimod o su sal sódica por vía oral; composición farmacéutica que comprende laquinimod y micofenolato mofetil. | |
| CR11731A (es) | Composiciones y procedimientos para su preparación y uso | |
| EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| BR112012008889A2 (pt) | compostos de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes | |
| BR112012012529A2 (pt) | composto indol e seu uso farmacêutico | |
| BRPI0709581A8 (pt) | compostos de bicicloeteroarila como moduladores de px27 e seu uso | |
| EA033311B1 (ru) | Производные бензоксаборола в качестве антибактериальных средств | |
| MX2011010311A (es) | Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas. | |
| BRPI1013763A2 (pt) | Composto ou sal do mesmo, prodroga, composição farmacêutica, agente diminuidor da proteína de ligação de retinol 4, agente para a profilaxia ou tratamento de diabetes, e, uso de um composto | |
| MX2011009847A (es) | Agentes antihelminticos y su uso. | |
| EA201100750A1 (ru) | Замещенные диоксопиперидинилфталимидные производные | |
| EA201070327A1 (ru) | Катехоламиновые производные и их пролекарства | |
| BRPI1007092A2 (pt) | "derivados de hidroxamato, uso dos derivados de hidroxamato, composições farmacêuticas, método para prevenção ou tratamento de doença e método de produção de derivados de hidroxamato" | |
| EA201001747A1 (ru) | Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств | |
| BRPI0922870A8 (pt) | uso de ao menos um composto da fórmula i, do composto ohod ou seus derivados farmaceuticamente aceitáveis, do composto na-ohod, composição farmacêutica e/ou nutracêutica e método cosmético | |
| MX2009010374A (es) | Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos. | |
| CL2009001267A1 (es) | Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis. | |
| WO2009130422A3 (fr) | N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog | |
| BR112012015170A2 (pt) | "derivado de amino-heteroarila, composição farmacêutica, uso de um derivado de amino-heteroarila, e, método para tratamento de dor." |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: ORGANON BIOSCIENCES NEDERLAND B.V. (NL) |
|
| B25A | Requested transfer of rights approved |
Owner name: MERCK SHARP AND DOHME B.V. (NL) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |